These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11167087)

  • 41. Receptor protein-tyrosine kinases and their signal transduction pathways.
    van der Geer P; Hunter T; Lindberg RA
    Annu Rev Cell Biol; 1994; 10():251-337. PubMed ID: 7888178
    [No Abstract]   [Full Text] [Related]  

  • 42. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
    Pegram MD; Lipton A; Hayes DF; Weber BL; Baselga JM; Tripathy D; Baly D; Baughman SA; Twaddell T; Glaspy JA; Slamon DJ
    J Clin Oncol; 1998 Aug; 16(8):2659-71. PubMed ID: 9704716
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials.
    Rugo H; Brammer M; Zhang F; Lalla D
    Clin Breast Cancer; 2010 Aug; 10(4):288-93. PubMed ID: 20705561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas.
    Padhy LC; Shih C; Cowing D; Finkelstein R; Weinberg RA
    Cell; 1982 Apr; 28(4):865-71. PubMed ID: 7094016
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars.
    Barbier L; Declerck P; Simoens S; Neven P; Vulto AG; Huys I
    Br J Cancer; 2019 Jul; 121(3):199-210. PubMed ID: 31257362
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trastuzumab cardiotoxicity: from clinical trials to experimental studies.
    Nemeth BT; Varga ZV; Wu WJ; Pacher P
    Br J Pharmacol; 2017 Nov; 174(21):3727-3748. PubMed ID: 27714776
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
    Zhu ZL; Zhang J; Chen ML; Li K
    Asian Pac J Cancer Prev; 2013; 14(12):7111-6. PubMed ID: 24460260
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
    McKeage K; Perry CM
    Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
    Saura C; Oliveira M; Feng YH; Dai MS; Chen SW; Hurvitz SA; Kim SB; Moy B; Delaloge S; Gradishar W; Masuda N; Palacova M; Trudeau ME; Mattson J; Yap YS; Hou MF; De Laurentiis M; Yeh YM; Chang HT; Yau T; Wildiers H; Haley B; Fagnani D; Lu YS; Crown J; Lin J; Takahashi M; Takano T; Yamaguchi M; Fujii T; Yao B; Bebchuk J; Keyvanjah K; Bryce R; Brufsky A;
    J Clin Oncol; 2020 Sep; 38(27):3138-3149. PubMed ID: 32678716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
    Geyer CE; Forster J; Lindquist D; Chan S; Romieu CG; Pienkowski T; Jagiello-Gruszfeld A; Crown J; Chan A; Kaufman B; Skarlos D; Campone M; Davidson N; Berger M; Oliva C; Rubin SD; Stein S; Cameron D
    N Engl J Med; 2006 Dec; 355(26):2733-43. PubMed ID: 17192538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-radioactive and sensitive tracking of neutrophils towards inflammation using antibody functionalized magnetic particle imaging tracers.
    Chandrasekharan P; Fung KLB; Zhou XY; Cui W; Colson C; Mai D; Jeffris K; Huynh Q; Saayujya C; Kabuli L; Fellows B; Lu Y; Yu E; Tay ZW; Zheng B; Fong L; Conolly SM
    Nanotheranostics; 2021; 5(2):240-255. PubMed ID: 33614400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disrupting Insulin and IGF Receptor Function in Cancer.
    Cao J; Yee D
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33429867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer.
    Decker JT; Kandagatla P; Wan L; Bernstein R; Ma JA; Shea LD; Jeruss JS
    Cancer Biol Ther; 2020 Nov; 21(11):994-1004. PubMed ID: 33054513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype.
    Oatmen KE; Cull E; Spinale FG
    Nat Rev Cardiol; 2020 Aug; 17(8):523-531. PubMed ID: 31686012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk Factors Associated with Trastuzumab-induced Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2-positive Breast Cancer.
    Abdel-Razaq W; Alzahrani M; Al Yami M; Almugibl F; Almotham M; Alregaibah R
    J Pharm Bioallied Sci; 2019; 11(4):348-354. PubMed ID: 31619917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trastuzumab-Associated Flagellate Erythema: Report in a Woman with Metastatic Breast Cancer and Review of Antineoplastic Therapy-Induced Flagellate Dermatoses.
    Cohen PR
    Dermatol Ther (Heidelb); 2015 Dec; 5(4):253-264. PubMed ID: 26506993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways.
    Guo L; Eldridge S; Furniss M; Mussio J; Davis M
    Curr Protoc Chem Biol; 2015 Sep; 7(3):141-185. PubMed ID: 26331525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.
    Mendler CT; Friedrich L; Laitinen I; Schlapschy M; Schwaiger M; Wester HJ; Skerra A
    MAbs; 2015; 7(1):96-109. PubMed ID: 25484039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Chitneni S; Zalutsky MR
    Nucl Med Biol; 2015 Jan; 42(1):19-27. PubMed ID: 25240914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.